Quest Diagnostics
846 hedge funds and large institutions have $15.2B invested in Quest Diagnostics in 2024 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 293 increasing their positions, 309 reducing their positions, and 73 closing their positions.
26% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 73
14% more capital invested
Capital invested by funds: $13.3B → $15.2B (+$1.82B)
10% more call options, than puts
Call options by funds: $62.2M | Put options by funds: $56.3M
1% more funds holding
Funds holding: 837 → 846 (+9)
0.11% more ownership
Funds ownership: 87.71% → 87.82% (+0.11%)
5% less repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 309
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$552M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$121M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$51.1M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$47.9M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$117M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$84.3M |
| 3 |
8KM
8 Knots Management
Dallas,
Texas
|
-$68.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$62.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$62.6M |
DGX Hedge Fund Activity: Q3 2024 in Review
846 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q3 2024, worth a combined $15.2B — up 14% from $13.3B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new DGX positions and 73 closed out — a net gain of 19 holders — while 293 added to existing stakes and 309 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $552M. The largest seller was Millennium Management, cutting an estimated $117M.
- 846 institutional investors held Quest Diagnostics (DGX) as of Q3 2024, up from 837 in Q2 2024.
- Funds reported $15.2B of Quest Diagnostics stock for Q3 2024, up 14% quarter-over-quarter.
- 92 funds opened new Quest Diagnostics positions in Q3 2024 and 73 closed out, a net change of +19 holders.
- The largest Quest Diagnostics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $552M added.
- The largest Quest Diagnostics seller in Q3 2024 was Millennium Management, an estimated $117M sold.
Based on aggregated 13F filings for Q3 2024.